The Center for Biosimilars® recaps the top news for the week of November 12, 2018.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 12.
Number 5: The Canadian Agency for Drugs and Technologies in Health has released a new report that explores international pricing policies related to biosimilars and the factors that facilitate their use.
Number 4: During its investor call last week, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta.
Number 3: A newly published systematic review investigated the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders.
Number 2: Given the high cost of biologics that treat pediatric inflammatory bowel disease, biosimilars are emerging as an important cost-saving option that can prevent the premature termination of biologic therapy for financial reasons.
Number 1: Genentech recently filed a motion in a US district court seeking an injunction to block JHL Biotech from making and selling potential biosimilars after former Genentech employees were charged with conspiring to steal trade secrets.
Finally, last week, our e-newsletter asked if requiring manufacturers to disclose their insulin’s list pricing process would help curb costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.